Canaccord Genuity and Jonestrading initiate "buy" ratings on TriSalus Life Sciences (TLSI) with target prices of $12.00 and $16.00.

Canaccord Genuity Group and Jonestrading have both initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a "buy" rating and $12.00 and $16.00 price targets respectively. Canaccord's target price suggests a potential upside of 67.60% from the company's current price. TriSalus Life Sciences reported ($1.56) EPS for the last quarter with revenue of $5.72M.